2021 TDDW
Symposium (XII) ORGAN-GUT AXIS: INNOVATION TO PRACTICE
MICROBIOTA AND CARDIOVASCULAR DISEASES Wei-Kai Wu Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan The gut microbiota plays an essential role in the development of cardiovascular disease through both immune-mediated and metabolite-mediated pathways. Shared pathogenic features have been observed between cardiovascular disease and dysbiosis, including chronic inflammation, insulin resistance and an imbalanced energy expenditure. Studies have also demonstrated a significant association between gut microbiota and cardiovascular disease and some microbiotadependent molecules are identified as signals that protect or induce cardiovascular phenotypes. Butyrate-producing bacteria such as Akkermansia muciniphila, Faecalibacterium prausnitzii, and Roseburia intestinalis were found to be depleted in patients with cardiovascular disease and have
exhibited protective effects for atherosclerosis in animal studies. At molecular level, structure components of bacteria such as lipopolysaccharide and gut microbiota-derived metabolites, including trimethylamine N-oxide, indoxyl sulphate, and phenylacetylglutamine, have shown causative effects on atherosclerotic plaque formation and enhanced thrombosis potential. Thus, the gut microbiota is becoming a potential target for the development of an intervention in preventing or treating cardiovascular disease. Further studies are required to elucidate key pathophysiological pathways from host-microbe interactions which can be manipulable to improve outcomes in patients with cardiovascular disease.
71
